Vergoeding 2016-2020 voor ATC-subgroep A10BJ : Glucagonachtig peptide-1-agonisten (glp-1-agonisten)
- Raming voor de totale Zvw-populatie
| 2016 | 2017 | 2018 | 2019 | 2020 | |
|---|---|---|---|---|---|
| A10BJ01 Exenatide (Bydureon ®) | 1.130.000 | 1.006.100 | 879.410 | 727.920 | 567.690 |
| A10BJ02 Liraglutide (Victoza ®) | 12.055.400 | 12.161.200 | 13.666.100 | 13.766.500 | 11.448.500 |
| A10BJ03 Lixisenatide (Lyxumia ®) | 35.703 | 51.647 | 90.202 | 83.478 | 62.650 |
| A10BJ05 Dulaglutide (Trulicity ®) | 622.090 | 1.699.200 | 2.757.000 | 2.636.800 | 3.517.800 |
| A10BJ06 Semaglutide (Ozempic ®) | . | . | 380.020 | 9.253.700 | 23.441.800 |
| Totaal | 13.843.193 | 14.918.147 | 17.772.732 | 26.468.398 | 39.038.440 |